CD13 as a new tumor target for antibody-drug conjugates: validation with the conjugate MI130110
CD13 as a new tumor target for antibody-drug conjugates: validation with the conjugate MI130110
About this item
Full title
Author / Creator
Publisher
England: BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
In the search for novel antibody-drug conjugates (ADCs) with therapeutic potential, it is imperative to identify novel targets to direct the antibody moiety. CD13 seems an attractive ADC target as it shows a differential pattern of expression in a variety of tumors and cell lines and it is internalized upon engagement with a suitable monoclonal ant...
Alternative Titles
Full title
CD13 as a new tumor target for antibody-drug conjugates: validation with the conjugate MI130110
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_38476467c1d24e7b8130be99558bbb30
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_38476467c1d24e7b8130be99558bbb30
Other Identifiers
ISSN
1756-8722
E-ISSN
1756-8722
DOI
10.1186/s13045-020-00865-7
